S31 - MS Therapeutics and Clinical Research II

Event Time: Wednesday April 26, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Dalfampiridine improves cognitive impairment in multiple sclerosis (MS): results from a randomised, double-blind, placebo-controlled trial Laura De Giglio
Disclosure:
Dr. De Giglio has received personal compensation for activities with Sanofi Genzyme, Novartis, Biogen, Teva, and EMD Serono.

1:12 PM 002 Rapidity of Onset of Ocrelizumab Clinical Efficacy in Relapsing Multiple Sclerosis Stephen Hauser, MD
Disclosure:
Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Symbiotix, Annexon, Bionure, Molecular Stethoscope. Dr. Hauser has received compensation for serving on the Board of Directors of Neurona.

1:24 PM 003 Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up Carrie Hersh, DO
Disclosure:
Dr. Hersh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva, and Genzyme. Dr. Hersh has received research support from Biogen Idec and Genentech.

1:36 PM 004 Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study Robert Naismith, MD
Disclosure:
Dr. Naismith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genentech, Genzyme, Novartis, and Teva. Dr. Naismith has received personal compensation in an editorial capacity for NEJM Journal Watch.

1:48 PM 005 Benign multiple sclerosis in the era of disease modifying therapies Camilo Diaz-Cruz, MD
Disclosure:
Dr. Diaz-Cruz has nothing to disclose.

2:00 PM 006 Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience Brandi Vollmer
Disclosure:
Dr. Vollmer has nothing to disclose.

2:12 PM 007 Alternate dosing of fingolimod for Multiple Sclerosis Ilya Kister, MD
Disclosure:
Dr. Kister has nothing to disclose.

2:24 PM 008 A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients with relapse of multiple sclerosis: Oral-CORTEM trial. Ferran Torres
Disclosure:
Dr. Torres has nothing to disclose.

Register Now

Related Courses